Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early aggressive lipid lowering for plaque reversal in familial hypercholesterolemia
NL-OMON49626Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ezetimibe in familial hypercholesterolemia (FH) and atherosclerosis, sponsored by Amsterdam University Medical Center. Primary endpoint: Mean plaque progression. Started Jul 2021; status: recruiting.
02
Drugs
ezetimibe
03
Conditions
familial hypercholesterolemia (FH)atherosclerosis
Beyond the preview
Go deeper on NL-OMON49626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49626.